Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.

ABSTRACT:

Aim

There have been no previous reports on the efficacy and safety of suvorexant for insomnia in people with psychiatric disorders.

Methods

This one-week, prospective, single-arm, clinical trial of fixed dose of suvorexant (20 mg if ages 18-64 or 15 mg if age ≥ 65 years) for insomnia included 57 patients with psychiatric disorders who had experienced any of the following insomnia symptoms for four or more nights during the week prior to the start of the study: total sleep time (TST) <6 hours, time to sleep onset (TSO) ≥30 minutes, or two or more episodes of wake after sleep onset.

Results

The mean age of the patients was 49.4 ± 17.3 years; 54.4% were women, 49.1% had a major depressive disorder, and 77.2% completed the trial. Compared with the baseline scores (the mea

SUBMITTER: Kishi T 

PROVIDER: S-EPMC7292311 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature